Javid Moslehi

Physician-Scientist, Section Chief, Cardio-Oncology & Immunology @UCSF

[Javid Moslehi @CardioOncology]

The Moslehi laboratory is recruiting a post-doctoral fellow with a PhD in immunology or molecular biology.
See below!
https://t.co/frfCFvfz5o
Below information about the lab:
https://t.co/xN3qDdqMvA
Interested candidates can email me with CV!
[email protected]

[DrJE-Salem @DrJESalem]

Thrille to share our latest work @NatureMedicine .
In 100K French cancer patients starting immune checkpoint inhibitors, COVID-19 vaccine around ICI initiation associated with mild improved survival.
https://t.co/wRRUV3Evwu
#Cancer #Immunotherapy #Vaccination
@CardioOncology

[Enrico Ammirati @AmmiratiEnrico]

Our findings suggest a disruption of the PD-L1/PD-1 axis in lymphocytic acute myocarditis,
representing a potential target for future therapies.
@CardioOncology
@EricAdler17

https://t.co/aTMIyh9US6

[UC San Diego Cardiology @UCSDCardiology]

Cardiovascular Medicine Grand Rounds - Friday, September 25

@UCSDCardFellows @UCSDHealthSci @CardioOncology @UCSFCardiology

[Javid Moslehi @CardioOncology]

Excited to present about our efforts in #CardioImmunology & #myocarditis at UCSF. @AHAScience @BCVSearlyCareer @UCSFCardiology Can we learn to use Precision-TCR-Guided immunotherapy 2 treat inflammatory heart disease?

[Javid Moslehi @CardioOncology]

Huge congrats to @ScientistBaylis! Ricky is a @lab_owens & @NickLeeper78 trained vascular biologist and now cardiology/#CardioOnc fellow at @UCSFCardiology! @MedicineUVA @ChrisKramerMD @UVaMSTP @mghmedres @immunox @UCSFMedicine @LabMcnamara @UCSF_CVfellows @AHAScience

[UCSF Cardiology @UCSFCardiology]

Congratulations, Dr. Ricky Baylis, on receiving the 2026 Hellman Family Clinical-Translational Research Development Award! His project will leverage the #UCSFCardiology Myocarditis Center to advance our understanding of the immunobiology of human myocarditis. @ScientistBaylis

[Javid Moslehi @CardioOncology]

@AbbateAntonio @DukeHeartCenter @FudimMarat @jregan2012 @manesh_patelMD @robmentz @SudarRajagopal @UVACVRC Fantastic to see this Antonio! Hope you are doing well!

[Javid Moslehi @CardioOncology]

I had the opportunity to pay tribute to Sallan & Lipshultz’s pioneering contributions in this @CircAHA article reflecting on the evolution of cardio-oncology.
https://t.co/VsK3vSSTtQ
Grateful to revisit that history with one of its pioneers.

[Javid Moslehi @CardioOncology]

Some conversations are a reminder of where a field came from: What a pleasure to start the morning catching up with Stephen Sallan, a legend in pediatric oncology and one of the pioneers whose work helped lay the foundations of what we now call cardio-oncology! A little history.

[Javid Moslehi @CardioOncology]

Stephen Sallan and the late Steve Lipshultz helped define anthracycline cardiotoxicity in children, long before “cardio-oncology” had a name. Steve recently passed away, and this morning we reminisced about him and those early days.

[Javid Moslehi @CardioOncology]

Talk about a true giant. Steve Lipshultz was a pioneer in the field of #CardioOnc & an outstanding mentor & friend. RIP. @ICOSociety @ESCardioOnco @DrJESalem
https://t.co/otr1NT89Ml

[Javid Moslehi @CardioOncology]

@ksase Looking forward to #GCOS27

[UCSF Health @UCSFHospitals]

We’re leading a $9M effort to crack one of myocarditis’ biggest mysteries: Why immune cells attack the heart. The long-term goal is "turning off the T cells attacking the heart while leaving the rest of the immune system intact," Dr. Josiah Gerdts says. https://t.co/8gs67UVC72

[Javid Moslehi @CardioOncology]

There is no one who has contributed 2 care of ICI-M patients as much as @DrJESalem! Must read for any cardiologist & anyone in #CardioOnc! ICI Myocarditis and Myotoxicity! @CircAHA @bradleymaronmd @HeartDocSadiya @kejoynt @AHAScience @ESCardioOnco https://t.co/x6L29v5Whb

[Javid Moslehi @CardioOncology]

What a difference a year makes! I put @baik_alan in charge of the @UCSF pericaritis center 1 year ago. He has killed it! Building clinical program, launching trials, preclinical models! Bedside to bench & back 2 bedside the vision for #CardioImmunology at @UCSFCardiology!

[Javid Moslehi @CardioOncology]

Huge congratulations 2 @AmirZMunir on being named a finalist for the Katz award at #AHA26! @SarnoffCardio @UCSFCardiology @Transactivator @glynnis_bann @chaz_hong @CatMak23 @saptarsi_haldar @czbiohub

[Javid Moslehi @CardioOncology]

@AartiAsnaniMD @MKeykhaeiMD @AbeBayer @BidmcCvi @TuftsMedSchool Great work!!!

[Javid Moslehi @CardioOncology]

@DrChoueiri @tompowles1 @DanaFarber @DanaFarberNews @DanaFarber_GU @DFCI_NeoVax @harvardmed @DrChoueiri I think it was a LOT more hair! Lol! Great to have overlapped with for at least a part of the 19 years, especially the days when you were the only person clapping after a postdoc presentation in @kaelin_lab! (‘Cause we don’t do this in the @kaelin_lab!)

[Javid Moslehi @CardioOncology]

Great talk by @Dr_Mike_Fradley on arrhythmias in #CardioOnc! @ICOSociety @thecsanz @ISHR_AUS

[Javid Moslehi @CardioOncology]

If there’s one lesson from #ZEUS, it’s this: CVD is not one disease, and inflammation is not one pathway. We won’t succeed by broadly suppressing the immune system. Like oncology, we need to understand the specific biology driving specific diseases...and treat accordingly.

[Javid Moslehi @CardioOncology]

Congratulations to the investigators and patients who made the #ZEUS trial possible. Large cardiovascular outcome trials are enormously challenging, and well-executed negative trials are just as important as positive ones. They move the field forward.
https://t.co/VhCybsKk9v